HERTHENA-Lung02: Phase III trial of patritumab deruxtecan in EGFR-mutated NSCLC post EGFR TKI

This video article presents the phase III HERTHENA-Lung02 study protocol, investigating the use of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Subscribe:    / @videojournalofbiomedicine9543   Visit The Video Journal of Biomedicine: https://www.biomedicine.video/ Follow us on X:   / vjofbiomedicine   LinkedIn:   / video-journal-of-biomedicine   Facebook:   / videojournalbiomedicine   #cancer #egfr #nsclc #lungcancer